Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.45 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.42 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15733013 | 0.82 | ALDH1A1 (0.46) | ALDH1A1PKMMAPTL3MBTL1KDM4E | |
| SCHEMBL1491101 | 0.81 | MEN1 (0.58) | ALDH1A1PKML3MBTL1KDM4EMEN1 | |
| SCHEMBL1491137 | 0.80 | KDM4E (0.56) | ALDH1A1PKMMAPTL3MBTL1KDM4E | |
| SCHEMBL3605369 | 0.79 | GRM2 (0.49) | ALDH1A1PKMMAPTL3MBTL1KDM4E | |
| SCHEMBL28325985 | 0.79 | ALDH1A1 (0.44) | ALDH1A1PKMMAPTL3MBTL1KDM4E | |
| SCHEMBL1491114 | 0.79 | KDM4E (0.50) | ALDH1A1PKMKDM4EMEN1KMT2A | |
| SCHEMBL1491106 | 0.79 | KDM4E (0.46) | ALDH1A1PKMKDM4EKMT2APOLB | |
| SCHEMBL28866154 | 0.76 | ALDH1A1 (0.41) | ALDH1A1PKMMAPTL3MBTL1KDM4E | |
| SCHEMBL1491059 | 0.76 | NPBWR1 (0.48) | ALDH1A1PKMMAPTL3MBTL1KDM4E | |
| SCHEMBL10643199 | 0.75 | ALDH1A1 (0.50) | ALDH1A1PKMMAPTL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1506193-B9 | CARBAMATE-SUBSTITUTED PYRAZOLOPYRIDINES | ADVERIO PHARMA GMBH (DE) | 2026-02-18 | — | — | EP | disclosed |
| EP-1506193-B3 | CARBAMATE-SUBSTITUTED PYRAZOLOPYRIDINES | ADVERIO PHARMA GMBH (DE) | 2025-12-03 | — | — | EP | disclosed |
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-04-14 | — | — | US | disclosed |
| EP-2288603-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009150614-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-12-17 | — | — | WO | disclosed |
| EP-0944631-B1 | NOVEL SUBSTITUTED PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CARDIOCIRCULATORY DISEASES | BAYER HEALTHCARE AG (DE) | 2004-02-18 | — | — | EP | disclosed |
| CN-1122032-C | Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases | BAYER AG (DE) | 2003-09-24 | — | — | CN | disclosed |
| US-6451805-B1 | Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2002-09-17 | — | — | US | disclosed |
| CN-1238773-A | Novel Substituted Pyrazole Derivatives for the Treatment of Cardiovascular Diseases | BAYER AG (DE) | 1999-12-15 | — | — | CN | disclosed |
| EP-0944631-A1 | NOVEL SUBSTITUTED PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CARDIOCIRCULATORY DISEASES | BAYER AG (DE) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998023619-A1 | NOVEL SUBSTITUTED PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CARDIOCIRCULATORY DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 1998-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | ALDH1A1 3233/4885PKM 2177/4885MAPT 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.